Literature DB >> 23983347

The influence of phytotherapy on macroprolactinoma size.

Ivo Trogrlić1, Dragan Trogrlić, Zoran Trogrlić.   

Abstract

The study aims at demonstrating the efficiency of phytotherapy in macroprolactinoma downsizing. The comparison of phytotherapeutic (PT) efficiency leant on medical records submitted by the patients prior to the PT launch, indicating the diagnosis established based on the outcome of the nuclear magnetic resonance imaging (NMRI) and/or computed tomography (CT) of the affected site and bringing the results of field-of-vision examination and hormonal status determination. The insight into the documentation in reference provided the information on tumour size and prolactin levels. The data in reference were compared against medical records submitted following phytotherapy completion. This study brings the results of a five-year investigation into the influence of phytotherapy on the size of macroprolactinomas. In patients responsive to this kind of treatment, tumour regression was witnessed within 6 months of herbal remedy use. A substantial tumour downsizing was accompanied by vision restitution;namely, in a number of cases, sight impairments are the first indicators of tumour presence. The basic parameters used for phytotherapeutic efficiency estimation and follow-up were the size of the tumour and the state of the field-of-vision, established both prior to and following phytotherapy. The results of the study presented herein unequivocally demonstrated the efficiency of phytotherapy in macroprolactinoma tumour mass downsizing, providing therefore solid grounds for the implementation of phytotherapy as a novel treatment modality of this tumour cluster.

Entities:  

Keywords:  Phytotherapy; macroprolactinoma; visual field defect

Mesh:

Substances:

Year:  2011        PMID: 23983347      PMCID: PMC3746621          DOI: 10.4314/ajtcam.v9i2.15

Source DB:  PubMed          Journal:  Afr J Tradit Complement Altern Med        ISSN: 2505-0044


  7 in total

1.  Selective serotonin reuptake inhibitors.

Authors:  John R Geddes; Andrea Cipriani
Journal:  BMJ       Date:  2004-10-09

Review 2.  The pathogenesis of pituitary adenomas.

Authors:  A Levy; S L Lightman
Journal:  Clin Endocrinol (Oxf)       Date:  1993-06       Impact factor: 3.478

3.  Plurihormonal pituitary adenomas.

Authors:  B W Scheithauer; E Horvath; K Kovacs; E R Laws; R V Randall; N Ryan
Journal:  Semin Diagn Pathol       Date:  1986-02       Impact factor: 3.464

Review 4.  Hyperprolactinemia: etiology, diagnosis, and management.

Authors:  Peak Mann Mah; Jonathan Webster
Journal:  Semin Reprod Med       Date:  2002-11       Impact factor: 1.303

Review 5.  Ultrastructural diagnosis of human pituitary adenomas.

Authors:  E Horvath; K Kovacs
Journal:  Microsc Res Tech       Date:  1992-01-15       Impact factor: 2.769

6.  [Clinical and therapeutic aspects of prolactinoma in men].

Authors:  Gisele Rieffel Braucks; Erika Cesar de Oliveira Naliato; Ana Lúcia Osorio Tabet; Monica Roberto Gadelha; Alice Helena Dutra Violante
Journal:  Arq Neuropsiquiatr       Date:  2004-01-06       Impact factor: 1.420

7.  The influence of phytotherapy on prolactin level in macroprolactinoma patients.

Authors:  Ivo Trogrlić; Dragan Trogrlić; Zoran Trogrlić
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-10-02
  7 in total
  2 in total

1.  Treatment of glioblastoma with herbal medicines.

Authors:  Ivo Trogrlić; Dragan Trogrlić; Darko Trogrlić; Amina Kadrić Trogrlić
Journal:  World J Surg Oncol       Date:  2018-02-13       Impact factor: 2.754

2.  TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT.

Authors:  Ivo Trogrlić; Dragan Trogrlić; Zoran Trogrlić
Journal:  Afr J Tradit Complement Altern Med       Date:  2016-09-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.